SYBIL
Systems biology for the functional validation of genetic determinants of skeletal diseases
| Coordinatore | UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 15˙778˙074 € |
| EC contributo | 11˙968˙569 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2018-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF NEWCASTLE UPON TYNE
Organization address
address: Kensington Terrace 6 contact info |
UK (NEWCASTLE UPON TYNE) | coordinator | 1˙324˙244.00 |
| 2 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 1˙183˙954.00 |
| 3 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 892˙918.00 |
| 4 |
GATC BIOTECH AG
Organization address
address: JAKOB STADLER PLATZ 7 contact info |
DE (KONSTANZ) | participant | 849˙780.00 |
| 5 | POLYGENE AG | CH | participant | 832˙400.00 |
| 6 |
PRIMM SRL
Organization address
address: VIA OLGETTINA 58 contact info |
IT (MILANO) | participant | 699˙200.00 |
| 7 |
ALACRIS THERANOSTICS GMBH
Organization address
address: FABECKSTRASSE 60-62 contact info |
DE (BERLIN) | participant | 666˙516.00 |
| 8 |
UNIVERSITA DEGLI STUDI DI L'AQUILA
Organization address
address: PIAZZA VINCENZO RIVERA 1 contact info |
IT (L'AQUILA) | participant | 638˙400.00 |
| 9 |
UNIVERSITA DEGLI STUDI DI PAVIA
Organization address
address: STRADA NUOVA 65 contact info |
IT (PAVIA) | participant | 576˙100.00 |
| 10 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 576˙000.00 |
| 11 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 554˙300.40 |
| 12 |
UNIVERSITEIT ANTWERPEN
Organization address
address: PRINSSTRAAT 13 contact info |
BE (ANTWERPEN) | participant | 498˙000.00 |
| 13 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | participant | 480˙000.00 |
| 14 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 479˙100.00 |
| 15 |
CERTUS TECHNOLOGY ASSOCIATES LIMITED
Organization address
address: ABBEY ROAD 9 MOUNT PLEASANT contact info |
UK (EXETER) | participant | 477˙660.00 |
| 16 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 469˙800.00 |
| 17 |
EVERCYTE GMBH
Organization address
address: MUTHGASSE 18 contact info |
AT (WIEN) | participant | 430˙598.40 |
| 18 |
FINOVATIS
Organization address
address: COURS LAFAYETTE 68 contact info |
FR (LYON) | participant | 339˙598.20 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the age related factors contributing to these painful conditions. To achieve this goal SYBIL will gather complementary translational and transnational scientists, systems biologists, disease modellers, leading SMEs and industrialists that will perform in-depth characterisation (complete molecular phenotyping) of pre-clinical models (cellular and animal) for a variety of common and rare skeletal diseases. SYBIL will establish a systematic pipeline of in vitro, ex vivo and in vivo models of increasing complexity and will also make use of novel technologies such as iPS cells and exclusive ‘Virtual Patient’ software to identify potential therapeutic targets for further validation through simultaneous modelling of fundamental and complex physiological pathways. SYBIL will rely on i) an ‘Omics Knowledge Factory’ for systematically generating new knowledge on skeletal disease pathophysiology and to generate the relevant Omics profiles necessary to detect and validate new disease determinants, biomarkers and therapeutic targets for future clinical developments, and ii) a “Systems Biology Hub” to integrate the high-throughput and data-dense information, to gain a global understanding of pathophysiological commonalities between different skeletal diseases and recognize predominant shared pathways and mechanisms that may represent new targeted routes to treatment. SYBIL will also identify potential modifier genes and study the epigenome that will ultimately influence the timing and efficacy of new personalised treatments. Overall SYBIL achievements will tremendously boost the efficient pre-clinical assessment and development of therapeutics against skeletal diseases and thus indirectly reduce their social and healthcare burden.'